Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis

References

• National Institute of Health. Schizophrenia. Available at: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml [Last accessed June 9, 2017]. The National Institute of Mental Health Information Resource Center, Bethesda, MD; 2016
   Google Scholar
• Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care 2005;11(8 Suppl):S235-S41
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Schizophrenia spectrum and other psychotic disorders. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: APA; 2014
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014;5:43-62
   PubMedGoogle Scholar
• Miller BJ, Bodenheimer C, Crittenden K. Second-generation antipsychotic discontinuation in first episode psychosis: an updated review. Clin Psychopharmacol Neurosci 2011;9:45-53
   PubMedGoogle Scholar
• Quach PL, Mors O, Christensen TO, et al. Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Interv Psychiatry 2009;3:66-74
   PubMed Web of Science ®Google Scholar
• Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998;172:53-9
   PubMedGoogle Scholar
• McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996;22:201-22
   PubMed Web of Science ®Google Scholar
• Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-76
   PubMed Web of Science ®Google Scholar
• Altamura AC, Aguglia E, Bassi M, et al. Rethinking the role of long-acting atypical antipsychotics in the community setting. Int Clin Psychopharmacol 2012;27:336-49
   PubMed Web of Science ®Google Scholar
• Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 2014;29:1409-13
   PubMed Web of Science ®Google Scholar
• Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011;10:10
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-68
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Frois C, Cloutier M, et al. Factors associated with adherence to the HEDIS quality measure in Medicaid patients with schizophrenia. Am Health Drug Benefits 2016;9:399-410
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health-Syst Pharm 2015;72:378-89
   PubMed Web of Science ®Google Scholar
• Kim B, Lee SH, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1231-5
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Koen L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008;23:325-31
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9
   PubMed Web of Science ®Google Scholar
• Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 2015;169(1–3):393-9
   PubMed Web of Science ®Google Scholar
• Emsley R, Parellada E, Bioque M, et al. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol 2018;33:15-33
   PubMed Web of Science ®Google Scholar
• Taylor DM, Sparshatt A, O’Hagan M, et al. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort - a four-year mirror image study. Eur Psychiatry 2016;37:43-8
   PubMed Web of Science ®Google Scholar
• Williams W, McKinney C, Martinez L, et al. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery. J Med Econ 2016;19:469-76
   PubMed Web of Science ®Google Scholar
• Pilon D, Muser E, Lefebvre P, et al. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry 2017;17:207
   PubMed Web of Science ®Google Scholar
• National Committee for Quality Assurance. Plan all-cause readmissions. Washington, DC; 2017. Available at: www.ncqa.org [Last accessed February 1, 2018]
   Google Scholar
• Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54:508-16
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. Toronto: Academic; 1977
   Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat-Simul Comput 2009;38:1228-34
   Web of Science ®Google Scholar
• Zeng LN, Rogers J, Seidensticker S, et al. Statistical models for hospital readmission prediction with application to chronic obstructive pulmonary disease (COPD) patients. Proceedings of the 2014 International Conference on Industrial Engineering and Operations Management Bali, Indonesia, January 7–9, 2014
   Google Scholar
• SAS Institute Inc. SAS/STAT 9.2 User’s Guide, Second Edition. Cary, NC: SAS Institute Inc; 2009
   Google Scholar
• Invega Sustenna (R). Highlights of prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2018. Available at: https://www.invegasustenna.com/important-product-information [Last accessed April 18, 2017]
   Google Scholar
• Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010;11:2301-17
   PubMed Web of Science ®Google Scholar
• Baser O, Xie L, Pesa J, et al. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ 2015;18:357-65
   PubMed Web of Science ®Google Scholar
• Morrato EH, Parks J, Campagna EJ, et al. Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. J Comp Eff Res 2015;4:89-99
   PubMed Web of Science ®Google Scholar
• Kim B, Lee SH, Yang YK, et al. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophr Res Treat 2012;2012:560836
   PubMedGoogle Scholar
• Heres S, Reichhart T, Hamann J, et al. Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry 2011;26:297-301
   PubMed Web of Science ®Google Scholar
• Vyas NS, Gogtay N. Treatment of early onset schizophrenia: recent trends, challenges and future considerations. Front Psychiatry 2012;3:29
   PubMedGoogle Scholar